Andrew Kuykendall, MD, discusses the current treatment landscape for the patients with myelofibrosis and how this evolved over the last decade.
Andrew Kuykendall, MD, assistant member at the Moffitt Cancer Center, discusses the current treatment landscape for the patients with myelofibrosis (MF) and how this evolved over the last decade.
For a long time, Kuykendall says the only FDA-approved therapy for the treatment of patients with MF was ruxolitinib (Jakafi). Physicians relied on this therapy for almost a decade to treat disease-related symptoms and symptoms related to the spleen.
However, in August 2019, the FDA granted approval to fedratinib (Inrebic). Fedratinib is now available as treatment of patients with intermediate-2 or high-risk primary or secondary myelofibrosis, including post-polycythemia vera or post-essential thrombocythemia MF. Kuykendall says physicians have been waiting a long time for a new therapy to become approved in the setting of patients with MF.